Scandion Oncology AS (OSTO:SCOL)

kr 0.075 0.004 (5.63%) Market Cap: 17.61 Mil Enterprise Value: -5.06 Mil PE Ratio: 0 PB Ratio: 0.48 GF Score: 0/100

Q2 2024 Scandion Oncology A/S Earnings Call Transcript
Aug 29, 2024

kr0.16 (+3.23%)

Earnings
Q4 2023 Scandion Oncology A/S Earnings Call Transcript
Feb 28, 2024

kr0.688322 (-8.65%)

Earnings
Q2 2023 Scandion Oncology A/S Earnings Call Transcript
Aug 23, 2023

kr0.527612 (+2.11%)

Earnings
Q1 2023 Scandion Oncology A/S Earnings Call Transcript
May 26, 2023

kr0.466361 (-1.66%)

Earnings
Q4 2022 Scandion Oncology A/S Earnings Call Transcript
Feb 22, 2023

kr0.688322 (+7.08%)

Earnings
Q2 2022 Scandion Oncology A/S Earnings Call Transcript
Aug 25, 2022

kr2.11 (+2.21%)

Earnings
Q1 2022 Scandion Oncology A/S Earnings Call Transcript
May 19, 2022

kr4.55 (-3.60%)

Earnings
Q4 2021 Scandion Oncology A/S Earnings Call Transcript
Feb 17, 2022

kr4.28 (-0.14%)

Earnings

Q1 2023 Scandion Oncology A/S Earnings Call Transcript

May 26, 2023 / 08:00AM GMT

Release Date Price: kr0.466361 (-1.66%)

Transcript

Operator

Good morning, and welcome to the Q1 2023 earnings call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Francois Martelet, CEO. Please go ahead, sir.

Francois Martelet;S;CEO

Scandion Oncology A

/-

Thank you very much, and good morning to everyone. And welcome to our Q1 2023 interim report investor call. So as you heard, my name is Francois Martelet. I am the CEO of Scandion Oncology. With me today, we have our Chief Financial Officer, Johnny Stilou. Johnny and I will be updating you on the developments and financial results for the first quarter of 2023 as well as recent events.

We made indeed very good progress in the quarter with strong execution of our plan, progressing our clinical trials, and taking the first steps of our strategy to enter acute myeloid leukemia and other cancer with a huge unmet medical need. And I will speak about that in a minute or so.

Following our presentation, Johnny and I are delighted to answer any questions you

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.